gemcitabine has been researched along with sodium arsenite in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, JK; Lee, KH; Lee, KT; Rhee, JC; Yang, MH; Yang, S | 1 |
| Bang, S; Chung, MJ; Jo, JH; Kang, H; Lee, HS; Park, JY; Park, SW; Song, SY | 1 |
2 other study(ies) available for gemcitabine and sodium arsenite
| Article | Year |
|---|---|
KML001 enhances anticancer activity of gemcitabine against pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Arsenites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gemcitabine; Humans; Matrix Metalloproteinase 2; Pancreatic Neoplasms; Sodium Compounds; Vascular Endothelial Growth Factor C | 2015 |
KML001, an arsenic compound, as salvage chemotherapy in refractory biliary tract cancers: A prospective study.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenites; Biliary Tract Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Salvage Therapy; Sodium Compounds; Time Factors; Tomography, X-Ray Computed | 2019 |